Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials

被引：2
|
作者：
Wang, Bin [1 ]
Pan, Shuaixi [2 ]
Yao, Yue [1 ]
Zeng, Linxi [1 ]
Zhang, Guoqiang [1 ,3 ]
机构：
[1] Hebei Med Univ, Hosp 1, Dept Dermatol, 89 Donggang Rd, Shijiazhuang, Hebei, Peoples R China
[2] Hebei Med Univ, Dept Optometry, Shijiazhuang, Hebei, Peoples R China
[3] Natl Clin Res Ctr Skin Dis, Candidate Branch, Shijiazhuang, Hebei, Peoples R China
来源：
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY | 2022年 / 49卷 / 11期
关键词：
atopic dermatitis; baricitinib; Janus kinase inhibitor; MANAGEMENT; DUPILUMAB;
D O I：
10.1111/1440-1681.13704
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Atopic dermatitis (AD) is one of the most prevalent inflammatory skin diseases. Janus kinase (JAK) inhibitor baricitinib is a promising treatment for AD as shown in recent clinical trials. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) reporting the efficacy and safety of baricitinib. Data analysis was carried out using Cochrane Collaboration Review Manager 5.4 software and performed as risk ratios (RR) with 95% confidence intervals. Six RCTs involving a total of 2595 patients were included in the review. The meta-analysis revealed that patients in the baricitinib group had significantly higher rates achieving EASI75, EASI90, IGA-Response, SCORAD75, and Itch NRS improvement. Pooled analysis also showed no significant differences in treatment of emergent adverse events (TEAEs) between baricitinib and placebo groups. In conclusion, our meta-analysis showed that baricitinib has promising efficacy for moderate-to-severe AD with favourable safety files.
引用
收藏
页码：1139 / 1149
页数：11
相关论文
共 50 条
  • [41] Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
    Khattri, S.
    Brunner, P. M.
    Garcet, S.
    Finney, R.
    Cohen, S. R.
    Oliva, M.
    Dutt, R.
    Fuentes-Duculan, J.
    Zheng, X.
    Li, X.
    Bonifacio, K. M.
    Kunjravia, N.
    Coats, I.
    Cueto, I.
    Gilleaudeau, P.
    Sullivan-Whalen, M.
    Suarez-Farinas, M.
    Krueger, J. G.
    Guttman-Yassky, E.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2016, 136 (05) : S41 - S41
  • [42] Efficacy and safety of 611 for the treatment of moderate-to-severe atopic dermatitis in adults
    Zhang, Jianzhong
    Zhao, Yan
    Zhou, Qinghong
    Xu, Yuyu
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191 : I54 - I55
  • [43] Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines
    Agache, Ioana
    Song, Yang
    Posso, Margarita
    Alonso-Coello, Pablo
    Rocha, Claudio
    Sola, Ivan
    Beltran, Jessica
    Akdis, Cezmi
    Akdis, Mubeccel
    Brockow, Knut
    Chivato, Tomas
    del Giacco, Stefano
    Eiwegger, Thomas
    Eyerich, Kilian
    Gimenez-Arnau, Ana
    Gutermuth, Jan
    Guttman-Yassky, Emma
    Maurer, Marcus
    Ogg, Graham
    Ong, Peck Y.
    O'Mahony, Liam
    Schwarze, Jurgen
    Werfel, Thomas
    Canelo-Aybar, Carlos
    Palomares, Oscar
    Jutel, Marek
    ALLERGY, 2021, 76 (01) : 45 - 58
  • [44] Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis
    Attia Attia
    Abdelrahman Ibrahim Abushouk
    Hussien Ahmed
    Mohamed Gadelkarim
    Ahmed Elgebaly
    Zeinab Hassan
    Mohamed M. Abdel-Daim
    Ahmed Negida
    Clinical Drug Investigation, 2017, 37 : 439 - 451
  • [45] Efficacy and safety of systemic treatments for moderate-to-severe psoriasis: meta-analysis of randomized controlled trials
    Schmitt, J.
    Rosumeck, S.
    Thomaschewski, G.
    Sporbeck, B.
    Haufe, E.
    Nast, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2014, 170 (02) : 274 - 303
  • [46] Safety and Efficacy of Brodalumab for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis
    Attia, Attia
    Abushouk, Abdelrahman Ibrahim
    Ahmed, Hussien
    Gadelkarim, Mohamed
    Elgebaly, Ahmed
    Hassan, Zeinab
    Abdel-Daim, Mohamed M.
    Negida, Ahmed
    CLINICAL DRUG INVESTIGATION, 2017, 37 (05) : 439 - 451
  • [47] Bimekizumab for the treatment of moderate-to-severe plaque psoriasis: a meta-analysis of randomized clinical trials
    Wang, Yuqian
    Li, Sheng
    Bai, Juan
    Cai, Xiaoxuan
    Tang, Shunli
    Lin, Peiyi
    Sun, Qingmiao
    Qiao, Jianjun
    Fang, Hong
    THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2023, 14
  • [48] Comparison of efficacy of targeted therapies without topical corticosteroids for moderate-to-severe atopic dermatitis: systematic review and network meta-analysis
    Silverberg, J. I.
    Hong, H. C.
    Thyssen, J. P.
    Calimlim, B. M.
    Joshi, A. D.
    Teixeira, H. D.
    Collins, E. B.
    Crowell, M. M.
    Johnson, S. J.
    Armstrong, A. W.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 185 (03) : E130 - E131
  • [49] Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study
    Liu, Bo
    Song, Xiaoting
    Liao, Shuanglu
    Luan, Tingting
    Zhao, Zuotao
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 2023, 184 (10) : 966 - 974
  • [50] The efficacy and safety of oral microecological agents as add-on therapy for atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials
    Xue, Peiwen
    Qin, Haiyan
    Qin, Di
    Liu, Huilin
    Li, Juan
    Jin, Rongjiang
    Xiao, Xianjun
    CLINICAL AND TRANSLATIONAL ALLERGY, 2023, 13 (12)
12345